
    
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, 4-week
      trial of a fixed-dose combination of apocynin and paeonol (APPA) administered orally twice
      daily versus placebo twice daily. Approximately 150 subjects will be randomized to one of the
      two treatment groups.
    
  